So, what's got bioAffinity Technologies Inc. (BIAF) shares moving up on a Wednesday? It's not a blockbuster drug approval or a massive new contract. It's something arguably more foundational for a diagnostics company: getting doctors in a (virtual) room to talk about actually using its product.
The company announced it's hosting a live virtual physician roundtable on April 8. This kicks off a new webinar series called "CyPath Lung in Practice." Think of it less as a sales pitch and more as a clinical grand rounds session. A panel of pulmonologists will discuss how they integrate the noninvasive CyPath Lung test into their daily practice, complete with real patient case studies. The main goal? Helping other doctors diagnose those tricky indeterminate pulmonary nodules with more confidence.
The Doctor Will See Your Test Now
This is about moving from the lab to the clinic. The participating physicians plan to show how the test's results guide their next steps. For example, they'll discuss cases where it helped identify early Stage 1A lung cancer. Perhaps more compelling for patient care and cost containment, the company says the test can prevent "unnecessary invasive, risky and costly procedures" when it returns an "Unlikely" result for malignancy.
This educational push comes on the heels of some serious business momentum. In 2025, revenue from the CyPath Lung test jumped 87% year-over-year. Even more impressive, the number of tests performed soared 99%. Management is strategically steering the ship away from lower-margin lab services and full-speed ahead toward this flagship product. Hosting a roundtable for doctors is a logical next step to fuel that growth—if physicians understand and trust the test, they'll order more of it.
How the Test Works
For those keeping score at home, CyPath Lung isn't your average blood test. It uses a combo of advanced flow cytometry and artificial intelligence to analyze cell populations in a patient's sputum (that's phlegm, for the non-medical readers) for signs of cancer. The clinical data is promising: studies show it has 92% sensitivity and 88% accuracy for detecting malignancy in nodules smaller than 20 millimeters. In the world of early cancer detection, those are numbers that get attention.
A Technical Picture of Extreme Moves
Now, let's look at the stock chart, because it tells a story of wild swings. As of this move, BIAF is trading a whopping 145% above its 20-day simple moving average and 195.2% above its 100-day average. That's a dramatic short-term spike on top of what was already an improving intermediate trend.
But here's the crucial context: even with this pop, the shares are still down 54.17% over the past year. The stock is much closer to its 52-week low of 69 cents than its high of $46.53. It's a reminder that this is a stock that has seen severe volatility.
The Relative Strength Index (RSI) sits at 70.05, which technically puts it in overbought territory—a sign the recent buying frenzy might be getting a bit exhausted. Meanwhile, the Moving Average Convergence Divergence (MACD) indicator remains bullish, with the MACD line at 0.6641 sitting above the signal line at 0.3560.
- Key Resistance: $4.50
- Key Support: $4.00
The Bottom Line: bioAffinity Technologies shares were up 11.36% at $4.41. The company is betting that the path to sustained growth for CyPath Lung runs through doctor education. A roundtable discussion might seem like a soft catalyst, but for a commercial-stage diagnostics company, convincing physicians is the whole game. The technicals show a stock catching a strong bid, though it's climbing a very steep hill from its recent lows.
